Immunotherapy Platform That Conjugates Antigen to Complement C3-Targeted Liposomes Induces a Robust Adaptive Immune Response
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26114985 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von R G Barber und 5 weiteren Autor:innen. Beteiligte Einrichtung: WWAMI School of Medical Education, University of Alaska Anchorage, 3211 Providence Drive, Anchorage, AK 99508, USA. Hauptthemen laut MEDLINE: Liposomes, Complement C3, Adaptive Immunity, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Alaska Run for Women, NIH HHS.
Abstract (Originalsprache)
The activation of immunosuppressed antigen-presenting cells (APCs) in the tumor microenvironment is a key goal in modern cancer immunotherapy. Our laboratory utilizes a liposome-based immunotherapy platform that binds endogenous complement to deliver antigen, adjuvant, and therapeutic agents to APCs in vivo. The liposomes contain external linker groups, which readily bind complement protein C3, and mediate liposomal uptake via complement receptor 3 into APCs. To test the ability of a model antigen to bind to these external linker groups on C3-liposomes and elicit a robust adaptive immune response, we conjugated a modified ovalbumin peptide (OVA-C) to the liposomes and incorporated a toll-like receptor (TLR) 4 agonist, monophosphoryl lipid A (MPLA), in the liposomal membrane. Adaptive immune responses from C57BL/6 mice were analyzed by ELISA and ELISpot. Mice vaccinated with OVA-C liposomes elicited significantly greater humoral and cellular adaptive responses relative to controls. Furthermore, female mice vaccinated with MPLA + OVA-C liposomes produced significantly more IgG antibodies than males vaccinated with the same liposomes. In conclusion, antigen binding on the exterior of C3-liposomes markedly improves antigen loading efficiency and still allows for complement C3-targeted delivery to APCs. These data demonstrate the initiation of a robust cellular and humoral immune response using a new liposomal delivery platform.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- WWAMI School of Medical Education, University of Alaska Anchorage, 3211 Providence Drive, Anchorage, AK 99508, USA.
- Department of Biological Sciences, University of Alaska Anchorage, 3211 Providence Drive, Anchorage, AK 99508, USA.
ORCID-Profile: R G Barber, Steven Cherry, Holly A Martinson
Förderung
- NCI NIH HHS
- Alaska Run for Women
- NIH HHS
- NIGMS NIH HHS
- National Institute of General Medical Sciences of the National Institutes of Health
- National Cancer Institute of the National Institutes of Health
Zitieren
APA
Barber, R. G., Cherry, S., Stephens, S., Mann, K., Martinson, H. A., & Kullberg, M. (2025). Immunotherapy Platform That Conjugates Antigen to Complement C3-Targeted Liposomes Induces a Robust Adaptive Immune Response. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26114985
Vancouver
Barber RG, Cherry S, Stephens S, Mann K, Martinson HA, Kullberg M. Immunotherapy Platform That Conjugates Antigen to Complement C3-Targeted Liposomes Induces a Robust Adaptive Immune Response. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26114985
BibTeX
@article{Barber2025,
author = {Barber, R G and Cherry, Steven and Stephens, Sydney and Mann, Kristine and Martinson, Holly A and Kullberg, Max},
title = {Immunotherapy Platform That Conjugates Antigen to Complement C3-Targeted Liposomes Induces a Robust Adaptive Immune Response},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26114985}
}
EUVIMED